Which beta-blocker is considered cardioselective?

The correct choice of beta-blocker that is considered cardioselective is Betaxolol. Cardioselective beta-blockers primarily block beta-1 adrenergic receptors, which are mainly located in the heart. This selectivity leads to a decrease in heart rate and myocardial contractility, thus reducing the workload on the heart, making these medications particularly useful in treating conditions like hypertension and certain types of heart disease.

Betaxolol, specifically, is utilized for its selective action on the heart, allowing it to minimize potential side effects related to beta-2 receptor blockade, such as bronchoconstriction. This selectivity makes it a preferred choice for patients with respiratory issues or conditions where non-selective beta-blockers could exacerbate symptoms.

While Atenolol is also a cardioselective beta-blocker, Betaxolol is highlighted in this context for its application. Propafenone and Labetalol, on the other hand, are not considered cardioselective, as Labetalol has both beta-1 and beta-2 blocking activity, and Propafenone acts primarily as an antiarrhythmic agent but has non-selective beta-blocking properties as well. Understanding the distinction between these medications helps in selecting